Calidi Biotherapeutics Net Worth
Calidi Biotherapeutics Net Worth Breakdown | CLDI |
Calidi Biotherapeutics Net Worth Analysis
Calidi Biotherapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Calidi Biotherapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Calidi Biotherapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Calidi Biotherapeutics' net worth analysis. One common approach is to calculate Calidi Biotherapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Calidi Biotherapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Calidi Biotherapeutics' net worth. This approach calculates the present value of Calidi Biotherapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Calidi Biotherapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Calidi Biotherapeutics' net worth. This involves comparing Calidi Biotherapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Calidi Biotherapeutics' net worth relative to its peers.
To determine if Calidi Biotherapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Calidi Biotherapeutics' net worth research are outlined below:
| Calidi Biotherapeutics is way too risky over 90 days horizon | |
| Calidi Biotherapeutics has some characteristics of a very speculative penny stock | |
| Calidi Biotherapeutics appears to be risky and price may revert if volatility continues | |
| Calidi Biotherapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (22.21 M) with profit before overhead, payroll, taxes, and interest of 31 K. | |
| Calidi Biotherapeutics generates negative cash flow from operations | |
| Latest headline from gurufocus.com: Join Calidi Biotherapeutics Exclusive Live Investor Webinar and QA Session on July 24 ... |
Calidi Biotherapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Calidi Biotherapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Calidi Biotherapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Follow Calidi Biotherapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 24.03 M.Market Cap |
|
Project Calidi Biotherapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.56) | (1.64) | |
| Return On Capital Employed | (4.65) | (4.41) | |
| Return On Assets | (1.56) | (1.64) | |
| Return On Equity | (14.43) | (13.71) |
When accessing Calidi Biotherapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Calidi Biotherapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Calidi Biotherapeutics' profitability and make more informed investment decisions.
Evaluate Calidi Biotherapeutics' management efficiency
Calidi Biotherapeutics has return on total asset (ROA) of (1.1174) % which means that it has lost $1.1174 on every $100 spent on assets. This is way below average. Calidi Biotherapeutics' management efficiency ratios could be used to measure how well Calidi Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.64. The Calidi Biotherapeutics' current Return On Capital Employed is estimated to increase to -4.41. As of now, Calidi Biotherapeutics' Non Currrent Assets Other are increasing as compared to previous years. The Calidi Biotherapeutics' current Total Current Assets is estimated to increase to about 10.7 M, while Total Assets are projected to decrease to under 13.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.25 | 0.23 | |
| Tangible Book Value Per Share | 0.25 | 0.23 | |
| Enterprise Value Over EBITDA | (0.31) | (0.32) | |
| Price Book Value Ratio | 6.00 | 6.30 | |
| Enterprise Value Multiple | (0.31) | (0.32) | |
| Price Fair Value | 6.00 | 6.30 | |
| Enterprise Value | 3.2 B | 2.8 B |
Management at Calidi Biotherapeutics focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Enterprise Value Revenue 49.4238 |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Calidi Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Calidi Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Calidi Biotherapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Calidi Biotherapeutics time-series forecasting models is one of many Calidi Biotherapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Calidi Biotherapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Calidi Biotherapeutics Earnings per Share Projection vs Actual
Calidi Biotherapeutics Corporate Management
| Andrew Jackson | Chief Officer | Profile | |
| PharmD Santidrian | Head Officer | Profile | |
| Stephen Thesing | Chief Officer | Profile | |
| Thomas Herrmann | Managing Development | Profile | |
| Wendy Esq | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Calidi Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For more detail on how to invest in Calidi Stock please use our How to Invest in Calidi Biotherapeutics guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Calidi Biotherapeutics. If investors know Calidi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Calidi Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Calidi Biotherapeutics is measured differently than its book value, which is the value of Calidi that is recorded on the company's balance sheet. Investors also form their own opinion of Calidi Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Calidi Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Calidi Biotherapeutics' market value can be influenced by many factors that don't directly affect Calidi Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Calidi Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Calidi Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Calidi Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.